"Zero tariff of anticancer drugs" is expected to be broken

[China Pharmaceutical network industry news] recently, the news about the tariff reduction of anticancer drugs has aroused strong repercussions in the pharmaceutical market Some insiders said that this means that patients are expected to use imported drugs at a lower price In addition, the introduction of this policy will bring greater development space to China's innovative pharmaceutical enterprises "Reducing tariff is conducive to improving the innovation ability of innovative enterprises and expanding the follow-up product line", "it will make the international innovation achievement time enter the domestic market and promote the improvement of China's pharmaceutical innovation level", "in the medium and long term, it will promote China's enterprises to develop into enterprises and improve the competitiveness of domestic enterprises." In the interview, some industry figures said It is understood that in China, the research and development of anti-cancer drugs lags behind The high price of anti-cancer drugs is even more amazing Nowadays, the reduction of anti-cancer drug tariff and striving to reduce it to zero tariff will be a great boon for some patients For domestic pharmaceutical enterprises, although it will bring a large degree of price and profit pressure in a short time, in the long term, it will undoubtedly help to improve the innovation ability of innovative pharmaceutical enterprises in China Adjusting the import tax rate of tumor drugs to zero will not only help tumor drugs enter the Chinese market, improve the enthusiasm of current imported drug companies, but also help to improve the access of innovative tumor drugs newly approved for research and development in the international market to the Chinese market, and promote the innovation and research of tumor drugs in China In addition, with the implementation of zero tariff for imported tumor drugs, tumor targeted drugs encouraged by the national health insurance policy will be more abundant, and the market is expected to usher in a big outbreak Cancer has become a major cause of death for urban residents in China It is urgent to reduce the price of life-saving drugs But at present, the research and development ability of anti-cancer drugs in China is low, the cycle is long and the difficulty is large, which brings great resistance to the supply of anti-cancer drugs Reducing the tariff of anticancer drugs will promote the international innovation time to enter the domestic market and improve the innovation level of anticancer drugs in China Some experts said that domestic innovative drug enterprises should speed up the layout, research, development and production of more high-quality cancer treatment products, and maintain competitiveness in product quality and price In the future development, Chinese pharmaceutical enterprises should continue to increase R & D and develop new models of new drug R & D It is understood that there is a large gap between China's new cancer drugs and developed countries According to relevant data, from 2010 to 2014, only 6 of the 49 new drugs were listed in China, and China's ranking of new cancer drugs' accessibility in the world is far lower than the United States and the United Kingdom and other developed countries Relevant experts said that the research and development of innovative drugs is a systematic project, and China needs the joint efforts of the government, pharmaceutical enterprises, hospitals and medical personnel to increase the research and development of new cancer drugs, improve the accessibility of new cancer drugs, and develop new models of new drug research and development There is still a big gap between China's cancer innovative drug market and foreign markets, but some insiders also point out that China's innovative drug market is not without its advantages It is understood that in recent years, with the national policy support in the field of innovative drugs, some enterprises have begun to increase investment in R & D, constantly enrich the R & D pipeline of innovative drugs, and cancer innovative drugs have made some achievements in R & D For example, Chenxin pharmaceutical has invested more than 100 million yuan in R & D every year, and the targeted antitumor drugs wx390 and DPP-4 hypoglycemic drug hingliptin have been approved for clinical use; the R & D investment of Shiyao group has been increased continuously, paclitaxel albumin has been listed in the market for 18 years, and the tumor product group has grown rapidly In addition, China's pharmaceutical enterprises have been in the global echelon in the clinical research of car-t therapy for hematoma Cancer prevention and treatment has brought a heavy burden to patients' families The news of the reduction of anti-cancer drug tariff undoubtedly brings good news to cancer patients However, China still needs to make continuous efforts in the research and development of anti-cancer drugs Interdisciplinary scientists and pharmaceutical enterprises should strengthen cooperation to promote the research and development of innovative drugs At the same time, China should introduce relevant supporting policies for the transformation of innovative drug achievements, give some tax incentives to pharmaceutical innovation enterprises, and increase the reinvestment of enterprise innovation I believe that with the concerted efforts of various forces, China's anti-cancer drugs will make greater breakthroughs in innovation.